DiaMedica Therapeutics Inc (NASDAQ:DMAC)

4.24
Delayed Data
As of 3:59pm ET
 +0.18 / +4.43%
Today’s Change
1.70
Today|||52-Week Range
8.80
-12.58%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$77.2M

Company Description

DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

Contact Information

DiaMedica Therapeutics, Inc.
2 Carlson Parkway
Minneapolis Minnesota 55447
P:(763) 612-6755
Investor Relations:
(763) 496-5118

Employees

Shareholders

Mutual fund holders2.90%
Other institutional14.24%
Individual stakeholders1.79%

Top Executives

Rick John PaulsPresident. Chief Executive Officer & Director
Scott KellenChief Financial Officer & Secretary
Harry W. AlcornChief Medical Officer
Sydney GilmanVice President-Regulatory Affairs